WHO Recommends New Ebola Vaccine Candidates for DRC Trial

Expert groups convened by the WHO have recommended adding two new Ebola vaccine candidates, ChAdOx1 (Oxford/Serum Institute of India) and Moderna's mRNA-1469, to the Tumaini clinical trial in the Democratic Republic of the Congo. These are the first vaccines specifically designed to protect against the Bundibugyo virus, which is responsible for the current outbreak. Their inclusion marks a significant step in evaluating new preventative measures during an active outbreak.